Editorial: Targeting TNF/TNFR signaling pathways.

Liqiang Pan,James J Chou,Tianmin Fu

DOI: https://doi.org/10.3389/fphar.2022.1120954

IF: 5.6

2023-01-01

Frontiers in Pharmacology

Abstract:EDITORIAL article Front. Pharmacol., 04 January 2023Sec. Experimental Pharmacology and Drug Discovery Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1120954

What problem does this paper attempt to address?

Selective Targeting of TNF Receptors as a Novel Therapeutic Approach

Roman Fischer,Roland E. Kontermann,Klaus Pfizenmaier

DOI: https://doi.org/10.3389/fcell.2020.00401

IF: 5.5

2020-05-26

Frontiers in Cell and Developmental Biology

Abstract:Tumor necrosis factor (TNF) is a central regulator of immunity. Due to its dominant pro-inflammatory effects, drugs that neutralize TNF were developed and are clinically used to treat inflammatory and autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. However, despite their clinical success the use of anti-TNF drugs is limited, in part due to unwanted, severe side effects and in some diseases its use even is contraindicative. With gaining knowledge about the signaling mechanisms of TNF and the differential role of the two TNF receptors (TNFR), alternative therapeutic concepts based on receptor selective intervention have led to the development of novel protein therapeutics targeting TNFR1 with antagonists and TNFR2 with agonists. These antibodies and bio-engineered ligands are currently in preclinical and early clinical stages of development. Preclinical data obtained in different disease models show that selective targeting of TNFRs has therapeutic potential and may be superior to global TNF blockade in several disease indications.

cell biology,developmental biology
TNF receptors: Structure-function relationships and therapeutic targeting strategies

Chih Hung Lo

DOI: https://doi.org/10.1016/j.bbamem.2024.184394

Abstract:Tumor necrosis factor receptors (TNFR1 and TNFR2) play key roles in mediating inflammatory response and cell death signaling, which are associated with autoimmune disorders, neurodegenerative diseases, and cancers. The structure-function relationships of TNF receptors and their ligands determine the activation or inhibition of downstream signaling pathways. Available crystal structures have provided critical insights into the therapeutic targeting strategies of TNF receptors and their signaling networks. In this review, we discuss the potential of targeting receptor-ligand and receptor-receptor interactions in a competitive manner as well as perturbing receptor conformational dynamics through an allosteric mechanism to modulate TNF receptor signaling. We propose that conformational states of TNF receptors can act as a molecular switch in determining their functions and are important therapeutic targets. The knowledge of the structure-function relationships of TNF receptors can be applied to translational high-throughput drug screening and design of novel receptor-specific modulators with enhanced pharmacological properties.
Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer

Michael Croft,Shahram Salek-Ardakani,Carl F. Ware

DOI: https://doi.org/10.1038/s41573-024-01053-9

IF: 112.288

2024-10-25

Nature Reviews Drug Discovery

Abstract:The first anti-tumour necrosis factor (TNF) monoclonal antibody, infliximab (Remicade), celebrated its 25th anniversary of FDA approval in 2023. Inhibitors of TNF have since proved clinically efficacious at reducing inflammation associated with several autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease. The success of TNF inhibitors raised unrealistic expectations for targeting other members of the TNF superfamily (TNFSF) of ligands and their receptors, with difficulties in part related to their more limited, variable expression and potential redundancy. However, there has been a resurgence of interest and investment, with many of these cytokines or their cognate receptors now under clinical investigation as targets for modulation of autoimmune and inflammatory diseases, as well as cancer. This Review assesses TNFSF-targeted biologics currently in clinical development for immune system-related diseases, highlighting ongoing challenges and future directions.

pharmacology & pharmacy,biotechnology & applied microbiology
Research advance of selective inhibitor of tumornecrosis factor receptor

Hailong JIANG,Ningyuan WANG,Yiming LU

DOI: https://doi.org/10.3969/j.issn.1006-0111.2015.05.003

2015-01-01

Abstract:TNF signaling pathway was a valuable target ,and anti-TNF drugs were successfully used to treat autoim-mune and inflammatory diseases .But this therapy abrogate some beneficial TNF signaling ,leading to increased risk of infection and malignancy ,and the onset of new auto-immune diseases .Inhibiting the soluble TNF/TNFR1 axis while saving the benefi-cial transmembrane TNF/TNFR2 signaling untouched was a new approach .Because it inhibited the pathological effects of TNF and reduced the side effects ,and opened the way for the treatment of other diseases in which TNFR2 inhibition was detrimen-tal .The significance of the selective inhibition of TNFR1-mediated signaling pathways for TNF-related diseases was discussed and the mechanism of TNF identification TNFR was clarified ,which might provide new ideas for the design of new drugs .
Therapeutic Potential of TNFα Inhibitors in Chronic Inflammatory Disorders: Past and Future

Hongtao Zhang,Nelson Shi,Zhuo Diao,Youhai Chen,Yejia Zhang

DOI: https://doi.org/10.1016/j.gendis.2020.02.004

IF: 7.376

2021-01-01

Genes & Diseases

Abstract:In the past 20 years, patients with rheumatoid arthritis (RA), Crohn's disease (CD), and other immune diseases have witnessed the impact of a great treatment advance with the availability of biological TNFα inhibitors. With 5 approved anti-TNFα biologics on the market and soon available biosimilars, patients have more treatment options and have benefited from understanding the biology of TNFα. Nevertheless, many unmet needs remain for people living with TNFα-related diseases, namely some side effects and tolerance of current anti-TNFα biologics and resistance to therapies. Furthermore, common diseases such as osteoarthritis and back/neck pain may respond to anti-TNFα therapies at early onset of symptoms. Development of new TNFα inhibitors focusing on TNFR1 specific inhibitors, preferably small molecules that can be delivered orally, is much needed.
TNF biology, pathogenic mechanisms and emerging therapeutic strategies

George D. Kalliolias,Lionel B. Ivashkiv

DOI: https://doi.org/10.1038/nrrheum.2015.169

IF: 32.286

2015-12-10

Nature Reviews Rheumatology

Abstract:Key PointsTNF is a pleiotropic cytokine that exerts homeostatic and pathogenic bioactivitiesA new concept in therapeutics of TNF-mediated diseases is the selective inhibition of the pathogenic effects of TNF with preservation of its homeostatic functionsTNF-induced necroptosis is a new pathway potentially implicated in TNF-mediated pathologiesTNF induces cellular priming, tolerization, and short-term transcriptional memory in a context-dependent mannerCombining TNF-blockade with drugs that target pathogenic pathways or cells not implicated in host defence is an attractive approach to improve effectiveness without compromising safety

rheumatology
Targeting of Costimulatory Molecules As a Therapeutic Approach in Inflammatory Bowel Disease

Philippe Maerten,Zhanju Liu,Jan L. Ceuppens

DOI: https://doi.org/10.2165/00063030-200317060-00003

IF: 7.744

2012-01-01

BioDrugs

Abstract:Crohn’s disease and ulcerative colitis are inflammatory bowel diseases (IBD) of unknown pathogenesis, for which no curative treatment is currently available. Although the recent introduction of agents designed to neutralise tumour necrosis factor has been an important achievement towards the control of Crohn’s disease, further development of more fundamental and non-toxic therapies is still required. One potential approach is the targeting of costimulatory membrane interactions between cells of the immune system. Costimulatory transmembrane ligands interact with receptors on target cells to enhance activation of the latter. Costimulatory interactions between antigen-presenting cells and T lymphocytes and between T lymphocytes and effector macrophages are of utmost importance for the activation of these cell types, which are all thought to be pivotal players in the immunopathology of IBD. Targeting these interactions with humanised monoclonal antibodies or soluble receptor fusion proteins is proposed as a potential new treatment modality of these often devastating pathologies. On the basis of experimental data, and in view of their essential role in the activation of antigen-presenting cells and T lymphocytes, the CD40/CD40 ligand and CD28/B7 interactions are likely to be the best targets for successful therapy.
Editorial: Advances on Targeted Nanomedicines for Atherosclerosis

Qinggong Han,Hongliang He,Yu Zhang

DOI: https://doi.org/10.3389/fphar.2022.1053938

IF: 5.6

2022-01-01

Frontiers in Pharmacology

Abstract:EDITORIAL article Front. Pharmacol., 14 October 2022Sec. Experimental Pharmacology and Drug Discovery Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1053938
Targeting TNFR2 for cancer immunotherapy: recent advances and future directions

Linxue Li,Ruiwei Ye,Yingying Li,Hanyu Pan,Sheng Han,Yiming Lu

DOI: https://doi.org/10.1186/s12967-024-05620-x

2024-09-02

Abstract:Cancer is the leading cause of death worldwide, accounting for nearly 10 million deaths every year. Immune checkpoint blockade approaches have changed the therapeutic landscape for many tumor types. However, current immune checkpoint inhibitors PD-1 or CTLA-4 are far from satisfactory, due to high immune-related adverse event incident (up to 60%) and the inefficiency in cases of "cold" tumor microenvironment. TNFR2, a novel hopeful tumor immune target, was initially proposed in 2017. It not only promotes tumor cell proliferation, but also correlates with the suppressive function of Treg cells, implicating in the development of an immunosuppressive tumor microenvironment. In preclinical studies, TNFR2 antibody therapy has demonstrated efficacy alone or a potential synergistic effect when combined with classical PD-1/ CTLA-4 antibodies. The focus of this review is on the characteristics, functions, and recent advancements in TNFR2 therapy, providing a new direction for the next generation of anti-tumor alternative therapy.
TNF in the liver: targeting a central player in inflammation

Gisa Tiegs,Andrea K. Horst

DOI: https://doi.org/10.1007/s00281-022-00910-2

2022-02-04

Seminars in Immunopathology

Abstract:Abstract Tumour necrosis factor-α (TNF) is a multifunctional cytokine. First recognized as an endogenous soluble factor that induces necrosis of solid tumours, TNF became increasingly important as pro-inflammatory cytokine being involved in the immunopathogenesis of several autoimmune diseases. In the liver, TNF induces numerous biological responses such as hepatocyte apoptosis and necroptosis, liver inflammation and regeneration, and autoimmunity, but also progression to hepatocellular carcinoma. Considering these multiple functions of TNF in the liver, we propose anti-TNF therapies that specifically target TNF signalling at the level of its specific receptors.

pathology,immunology
Editorial: Novel Targets and Biomarkers in Solid Tumors

Zhi Shi,Hui-Qin Guo,Pascale A. Cohen,Dong-Hua Yang

DOI: https://doi.org/10.3389/fphar.2019.00828

IF: 5.6

2019-01-01

Frontiers in Pharmacology

Abstract:EDITORIAL article Front. Pharmacol., 26 July 2019Sec. Experimental Pharmacology and Drug Discovery Volume 10 - 2019 | https://doi.org/10.3389/fphar.2019.00828
Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases

Praveen Krishna Veerasubramanian,Thomas A Wynn,Jie Quan,Fridrik J Karlsson

DOI: https://doi.org/10.1084/jem.20240806

2024-11-04

Abstract:Dysregulated signaling from TNF and TNFR proteins is implicated in several immune-mediated inflammatory diseases (IMIDs). This review centers around seven IMIDs (rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, psoriasis, atopic dermatitis, and asthma) with substantial unmet medical needs and sheds light on the signaling mechanisms, disease relevance, and evolving drug development activities for five TNF/TNFR signaling axes that garner substantial drug development interest in these focus conditions. The review also explores the current landscape of therapeutics, emphasizing the limitations of the approved biologics, and the opportunities presented by small-molecule inhibitors and combination antagonists of TNF/TNFR signaling.
Editorial: Novel therapeutic target and drug discovery for neurological diseases

Kaiyue Zhao,Zhuorong Li,Qingshan Liu,Yong Cheng,George E. Barreto,Rui Liu

DOI: https://doi.org/10.3389/fphar.2022.1042266

IF: 5.6

2022-01-01

Frontiers in Pharmacology

Abstract:EDITORIAL article Front. Pharmacol., 07 October 2022Sec. Neuropharmacology https://doi.org/10.3389/fphar.2022.1042266
TLR Signaling Pathways: Opportunities for Activation and Blockade in Pursuit of Therapy

Kasper Hoebe,Zuosheng Jiang,Philippe Georgel,Koichi Tabeta,Edwin Janssen,Xu Du,Bruce Beutler

DOI: https://doi.org/10.2174/138161206778743466

IF: 3.31

2006-01-01

Current Pharmaceutical Design

Abstract:The identification of the TLRs as key sensors of microbial infection has presented a series of new targets for drug development. The TLRs are linked to the most powerful inflammatory pathways in mammals. The question arises from the start: do we wish to stimulate TLR signaling in order to eradicate specific infections and/or neoplastic diseases? Or do we wish to block TLR signaling to treat inflammatory diseases? If we accept that it would be useful to modulate TLR signaling, the next step is to identify the correct molecular target(s) for the task. Perhaps it might even be possible to exercise selectivity, modulating some aspects of TLR signaling and not others. Classical and reverse genetic analyses offer insight into the possibilities that exist, and point to specific checkpoints within signaling pathways at which modulation might normally be imposed.
Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer

Muchun Li,Xiaozhen Zhang,Xueli Bai,Tingbo Liang

DOI: https://doi.org/10.3389/fonc.2022.862154

IF: 4.7

2022-01-01

Frontiers in Oncology

Abstract:Tumor necrosis factor (TNF) receptor type II (TNFR2) is expressed in various tumor cells and some immune cells, such as regulatory T cells and myeloid-derived suppressing cells. TNFR2 contributes a lot to the tumor microenvironment. For example, it directly promotes the occurrence and growth of some tumor cells, activates immunosuppressive cells, and supports immune escape. Existing studies have proved the importance of TNFR2 in cancer treatment. Here, we reviewed the activation mechanism of TNFR2 and its role in signal transduction in the tumor microenvironment. We summarized the expression and function of TNFR2 within different immune cells and the potential opportunities and challenges of targeting TNFR2 in immunotherapy. Finally, the advantages and limitations of TNFR2 to treat tumor-related diseases are discussed, and the problems that may be encountered in the clinical development and application of targeted anti-TNFR2 agonists and inhibitors are analyzed.
Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine–driven inflammation and fibrosis

Kevin M Vannella,Thirumalai R Ramalingam,Lee A Borthwick,Luke Barron,Kevin M Hart,Robert W Thompson,Kristen N Kindrachuk,Allen W Cheever,Sandra White,Alison L Budelsky,Michael R Comeau,Dirk E Smith,Thomas A Wynn,Kevin M. Vannella,Thirumalai R. Ramalingam,Lee A. Borthwick,Kevin M. Hart,Robert W. Thompson,Kristen N. Kindrachuk,Allen W. Cheever,Alison L. Budelsky,Michael R. Comeau,Dirk E. Smith,Thomas A. Wynn

DOI: https://doi.org/10.1126/scitranslmed.aaf1938

IF: 17.1

2016-05-04

Science Translational Medicine

Abstract:Combined blockade of TSLP, IL-25, and IL-33 may be needed to treat some forms of progressive inflammation and fibrosis.

cell biology,medicine, research & experimental
The Therapeutic Potential of Targeting CD40-TRAF6 Pathway in Cardiovascular Diseases

Peng Zhong,Minxiao Chen,Bin Kong,Hui Fu,Jingjing Zhang,He Huang

DOI: https://doi.org/10.1016/j.ijcard.2019.08.008

IF: 4.039

2019-01-01

International Journal of Cardiology

Abstract:The costimulatory CD40-CD40L receptor/ligand dyad is a well-known driver of atherosclerosis and other chronic inflammatory diseases [ [1] Seijkens T. T. P. van Tiel C. M. Kusters P. J. H. Atzler D. Soehnlein O. Zarzycka B. et al. Targeting CD40- induced TRAF6 signaling in macrophages reduces atherosclerosis. J. Am. Coll. Cardiol. 2018; 71: 527-542 Google Scholar ]. However, long-term inhibition of CD40 or CD40L results in immune suppression and/or thromboembolic events, and is therefore not feasible as a therapy [ [2] Ahonen C. Manning E. Erickson L. D. O'Connor B. Lind E. F. Pullen S. S. et al. The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat. Immunol. 2002; 3: 451-456 Google Scholar ].
Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents

Huimin Zou,Ruixin Li,Hao Hu,Yuanjia Hu,Xin Chen

DOI: https://doi.org/10.3389/fimmu.2018.00594

IF: 7.3

2018-03-26

Frontiers in Immunology

Abstract:There is now compelling evidence that tumor necrosis factor (TNF)-TNF receptor type II (TNFR2) interaction plays a decisive role in the activation, expansion, and phenotypical stability of suppressive CD4<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells (Tregs). In an effort to translate this basic research finding into a therapeutic benefit, a number of agonistic or antagonistic TNFR2-targeting biological agents with the capacity to activate or inhibit Treg activity have been developed and studied. Recent studies also show that thalidomide analogs, cyclophosphamide, and other small molecules are able to act on TNFR2, resulting in the elimination of TNFR2-expressing Tregs. In contrast, pharmacological agents, such as vitamin D3 and adalimumab, were reported to induce the expansion of Tregs by promoting the interaction of transmembrane TNF (tmTNF) with TNFR2. These studies clearly show that TNFR2-targeting pharmacological agents represent an effective approach to modulating the function of Tregs and thus may be useful in the treatment of major human diseases such as autoimmune disorders, graft-versus-host disease (GVHD), and cancer. In this review, we will summarize and discuss the latest progress in the study of TNFR2-targeting pharmacological agents and their therapeutic potential based on upregulation or downregulation of Treg activity.

immunology
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD

Giorgos Bamias,Paola Menghini,Theresa T Pizarro,Fabio Cominelli

DOI: https://doi.org/10.1136/gutjnl-2024-332504

IF: 24.5

2024-09-11

Gut

Abstract:TNF-like cytokine 1A (TL1A) and its functional receptor, death-domain receptor 3 (DR3), are members of the TNF and TNFR superfamilies, respectively, with recognised roles in regulating innate and adaptive immune responses; additional existence of a decoy receptor, DcR3, indicates a tightly regulated cytokine system. The significance of TL1A:DR3 signalling in the pathogenesis of inflammatory bowel disease (IBD) is supported by several converging lines of evidence. Herein, we aim to provide a comprehensive understanding of what is currently known regarding the TL1A/DR3 system in the context of IBD. TL1A and DR3 are expressed by cellular subsets with important roles for the initiation and maintenance of intestinal inflammation, serving as potent universal costimulators of effector immune responses, indicating their participation in the pathogenesis of IBD. Recent evidence also supports a homoeostatic role for TL1A:DR3 via regulation of Tregs and innate lymphoid cells. TL1A and DR3 are also expressed by stromal cells and may contribute to inflammation-induced or inflammation-independent intestinal fibrogenesis. Finally, discovery of genetic polymorphisms with functional consequences may allow for patient stratification, including differential responses to TL1A-targeted therapeutics. In conclusion, TL1A:DR3 signalling plays a central and multifaceted role in the immunological pathways that underlie intestinal inflammation, such as that observed in IBD. Such evidence provides the foundation for developing pharmaceutical approaches targeting this ligand-receptor pair in IBD.

gastroenterology & hepatology
[Biologics for Targeting Inflammatory Cytokines and Their Clinical Application].

Jin Chen,Mian Xie,Lujun Li,Dongxu Liu,Mengyuan Liu

DOI: https://doi.org/10.13345/j.cjb.190022

2019-01-01

Abstract:Inflammatory cytokines can mediate many biological processes and are tightly regulated by the body. Loss of control can trigger a range of diseases such as autoimmune inflammation and cancer. Therefore, a number of biological agents that can effectively regulate the biological effects of inflammatory cytokines such as recombinant anti-inflammatory cytokines, cytokine receptors and neutralizing antibodies have been extensively used in the treatment of related diseases caused by the imbalance of inflammatory cytokines. In recent years, in particular, a number of new innovative biological agents for blocking and regulating cytokine activities are emerging. In this article, we review the recent development and clinical use of the biologics targeting TNF-α, IL-1, IL-6 and IL-17, and point out their inherent limitations and clinical risks. Finally, based on the research findings of our own and other scholars, we suggest some approaches and methods for reducing their side-effects and clinical risk. We consider that using modern biotechnology to improve the tissue specificity to inflammatory site and tumor will be an important development direction of such biologics.

Editorial: Targeting TNF/TNFR signaling pathways.

Selective Targeting of TNF Receptors as a Novel Therapeutic Approach

TNF receptors: Structure-function relationships and therapeutic targeting strategies

Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer

Research advance of selective inhibitor of tumornecrosis factor receptor

Therapeutic Potential of TNFα Inhibitors in Chronic Inflammatory Disorders: Past and Future

TNF biology, pathogenic mechanisms and emerging therapeutic strategies

Targeting of Costimulatory Molecules As a Therapeutic Approach in Inflammatory Bowel Disease

Editorial: Advances on Targeted Nanomedicines for Atherosclerosis

Targeting TNFR2 for cancer immunotherapy: recent advances and future directions

TNF in the liver: targeting a central player in inflammation

Editorial: Novel Targets and Biomarkers in Solid Tumors

Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases

Editorial: Novel therapeutic target and drug discovery for neurological diseases

TLR Signaling Pathways: Opportunities for Activation and Blockade in Pursuit of Therapy

Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer

Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine–driven inflammation and fibrosis

The Therapeutic Potential of Targeting CD40-TRAF6 Pathway in Cardiovascular Diseases

Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents

Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD

[Biologics for Targeting Inflammatory Cytokines and Their Clinical Application].